Rapport Therapeutics (RAPP)

Executive Summary

Rapport Therapeutics (NASDAQ: RAPP) is a clinical-stage biopharmaceutical company pioneering precision medicines for neurological disorders by targeting receptor-associated proteins (RAPs). Its lead candidate, RAP-219, is a small molecule designed to modulate specific neural circuits with high selectivity, potentially improving efficacy and tolerability. RAP-219 has completed a Phase 2 trial in focal onset seizures (NCT06377930) and is currently being evaluated in Phase 2 studies for focal epilepsy (NCT07219407) and bipolar I disorder (NCT07046494). The company's innovative RAP platform aims to address the complexity of the brain, offering a novel approach to treat conditions like epilepsy and bipolar disorder. With a strong scientific foundation and a focused pipeline, Rapport is positioned to deliver meaningful advances in neurology. The company went public in May 2024 and has secured funding through private rounds prior to its IPO. As of early 2026, RAP-219's Phase 2 data in focal onset seizures are expected to read out, providing key validation of the platform. Rapport's success hinges on positive clinical outcomes and its ability to progress candidates through development.

Upcoming Catalysts (preview)

• Q1 2026RAP-219 Phase 2 Top-Line Data in Focal Onset Seizures70% success
• Q4 2026RAP-219 Phase 2 Data in Bipolar I Disorder60% success
• H2 2026Initiation of Phase 2 Trial for Next Pipeline Candidate (RAP-199 or undisclosed)40% success